PUBLISHER: TechNavio | PRODUCT CODE: 1915337
PUBLISHER: TechNavio | PRODUCT CODE: 1915337
Global Cancer Supportive Care Market 2025-2029
The global cancer supportive care market is forecasted to grow by USD 6723.5 mn during 2024-2029, accelerating at a CAGR of 4.4% during the forecast period. The report on the global cancer supportive care market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of cancer cases, many side effects associated with cancer treatment, untapped potential in developing countries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2029 |
| Series Year | 2025-2029 |
| Growth Momentum | Accelerate |
| YOY 2025 | 4.1% |
| CAGR | 4.4% |
| Incremental Value | $6723.5 mn |
Technavio's global cancer supportive care market is segmented as below:
By Therapeutic Area
- Chemotherapy-induced anemia
- Chemotherapy-induced neutropenia
- Cancer pain
- CINV
- Others
By Distribution Channel
- Hospitals pharmacies
- Drug stores and retail pharmacies
- Online providers
By Application
- Breast cancer
- Colorectal cancer
- Stomach cancer
- Liver cancer
- Prostate cancer
Geography
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- The Netherlands
- Spain
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the advent of biosimilars in cancer-associated treatment as one of the prime reasons driving the global cancer supportive care market growth during the next few years. Also, outsourcing of biosimilars manufacturing activities and adoption of various strategies will lead to sizable demand in the market.
The report on the global cancer supportive care market covers the following areas:
- Global cancer supportive care market sizing
- Global cancer supportive care market forecast
- Global cancer supportive care market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global cancer supportive care market vendors that include Amgen Inc., APR Applied Pharma Research SA, Baxter International Inc., Bayer AG, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Johnson and Johnson Services, Kyowa Kirin Co. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Ltd.. Also, the global cancer supportive care market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Therapeutic Area
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
5 Historic Market Size
- 5.1 Global Cancer Supportive Care Market 2019 - 2023
- Historic Market Size - Data Table on Global Cancer Supportive Care Market 2019 - 2023 ($ million)
- 5.2 Therapeutic Area segment analysis 2019 - 2023
- Historic Market Size - Therapeutic Area Segment 2019 - 2023 ($ million)
- 5.3 Distribution Channel segment analysis 2019 - 2023
- Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
- 5.4 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 The AI impact on Global Cancer Supportive Care Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
8 Market Segmentation by Therapeutic Area
- 8.1 Market segments
- 8.2 Comparison by Therapeutic Area
- 8.3 Chemotherapy-induced anemia - Market size and forecast 2024-2029
- 8.4 Chemotherapy-induced neutropenia - Market size and forecast 2024-2029
- 8.5 Cancer pain - Market size and forecast 2024-2029
- 8.6 CINV - Market size and forecast 2024-2029
- 8.7 Others - Market size and forecast 2024-2029
- 8.8 Market opportunity by Therapeutic Area
- Market opportunity by Therapeutic Area ($ million)
9 Market Segmentation by Distribution Channel
- 9.1 Market segments
- 9.2 Comparison by Distribution Channel
- 9.3 Hospitals pharmacies - Market size and forecast 2024-2029
- 9.4 Drug stores and retail pharmacies - Market size and forecast 2024-2029
- 9.5 Online providers - Market size and forecast 2024-2029
- 9.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
10 Market Segmentation by Application
- 10.1 Market segments
- 10.2 Comparison by Application
- 10.3 Breast cancer - Market size and forecast 2024-2029
- 10.4 Colorectal cancer - Market size and forecast 2024-2029
- 10.5 Stomach cancer - Market size and forecast 2024-2029
- 10.6 Liver cancer - Market size and forecast 2024-2029
- 10.7 Prostate cancer - Market size and forecast 2024-2029
- 10.8 Market opportunity by Application
- Market opportunity by Application ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- 12.3.1 US - Market size and forecast 2024-2029
- 12.3.2 Canada - Market size and forecast 2024-2029
- 12.3.3 Mexico - Market size and forecast 2024-2029
- 12.4 Europe - Market size and forecast 2024-2029
- 12.4.1 UK - Market size and forecast 2024-2029
- 12.4.2 Germany - Market size and forecast 2024-2029
- 12.4.3 France - Market size and forecast 2024-2029
- 12.4.4 Italy - Market size and forecast 2024-2029
- 12.4.5 The Netherlands - Market size and forecast 2024-2029
- 12.4.6 Spain - Market size and forecast 2024-2029
- 12.5 Asia - Market size and forecast 2024-2029
- 12.5.1 China - Market size and forecast 2024-2029
- 12.5.2 Japan - Market size and forecast 2024-2029
- 12.5.3 India - Market size and forecast 2024-2029
- 12.5.4 South Korea - Market size and forecast 2024-2029
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- 12.6.1 Brazil - Market size and forecast 2024-2029
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- 12.6.3 Argentina - Market size and forecast 2024-2029
- 12.6.4 Australia - Market size and forecast 2024-2029
- 12.6.5 UAE - Market size and forecast 2024-2029
- 12.6.6 Colombia - Market size and forecast 2024-2029
- 12.6.7 South Africa - Market size and forecast 2024-2029
- 12.6.8 Israel - Market size and forecast 2024-2029
- 12.6.9 Turkey - Market size and forecast 2024-2029
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Growing prevalence of cancer cases
- Many side effects associated with cancer treatment
- Untapped potential in developing countries
- 13.2 Market challenges
- High cost of cancer treatment
- Rising popularity of targeted therapies in developed countries
- Inadequate reimbursement policies
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Advent of biosimilars in cancer-associated treatment
- Outsourcing of biosimilars manufacturing activities
- Adoption of various strategies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.5 Baxter International Inc.
- Baxter International Inc. - Overview
- Baxter International Inc. - Business segments
- Baxter International Inc. - Key news
- Baxter International Inc. - Key offerings
- Baxter International Inc. - Segment focus
- SWOT
- 15.6 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.7 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.10 Helsinn Healthcare SA
- Helsinn Healthcare SA - Overview
- Helsinn Healthcare SA - Product / Service
- Helsinn Healthcare SA - Key offerings
- SWOT
- 15.11 Heron Therapeutics Inc.
- Heron Therapeutics Inc. - Overview
- Heron Therapeutics Inc. - Business segments
- Heron Therapeutics Inc. - Key offerings
- Heron Therapeutics Inc. - Segment focus
- SWOT
- 15.12 Johnson and Johnson Services
- Johnson and Johnson Services - Overview
- Johnson and Johnson Services - Business segments
- Johnson and Johnson Services - Key news
- Johnson and Johnson Services - Key offerings
- Johnson and Johnson Services - Segment focus
- SWOT
- 15.13 Kyowa Kirin Co. Ltd.
- Kyowa Kirin Co. Ltd. - Overview
- Kyowa Kirin Co. Ltd. - Business segments
- Kyowa Kirin Co. Ltd. - Key offerings
- Kyowa Kirin Co. Ltd. - Segment focus
- SWOT
- 15.14 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.15 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.17 Sun Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd. - Overview
- Sun Pharmaceutical Industries Ltd. - Product / Service
- Sun Pharmaceutical Industries Ltd. - Key news
- Sun Pharmaceutical Industries Ltd. - Key offerings
- SWOT
- 15.18 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
